100% of Lameplast Group to Aksìa Capital

The independent private equity firm Aksìa Group SGR SpA announced the acquisition of 100% of Lameplast Group, Italian and European leader in the preparation, filling and packaging of pharmaceutical products, medical devices and cosmetics.

The transaction was completed April 28, 2016. With sales of over 45 million euro in 2015, the Group operates through the two Italian companies, Lameplast SpA and COC Farmaceutici Srl, and the sales subsidiary LF of America in the United States.
Established in 1976 in Carpi, near Modena, Lameplast SpA manufactures single-dose containers and multi-dose strips, bottles and flacons of various size, droppers and other plastic packaging. The more than 30 press.molding lines annually produce 350 million pieces, obtained with different technologies, for the biggest names in the cosmetics and pharmaceutical industries.
With 25 years of experience in the pharmaceutical sector, COC Farmaceutici is in turn in a position to offer a complete production service on contract: from scientific research to product realization, up to the filling of the containers. Thanks to this vertical integration, Lameplast COC Group offers its customers - Italian and international companies in the pharmaceutical and health care, including Johnson & Johnson, Merck USA, Recordati, Chiesi Farmaceutici, Sooft and Molteni Farmaceutici - support at every stage of the production process.

The Aksìa Capital IV operation involves the acquisition of full ownership package from the three founders, who will continue to lead Lameplast COC Group: Giovanni Ferrari (President and CEO), Antonio Fontana and Evro Fabbri (as directors).
«We are very proud of this operation that allows our companies to look to the future with important goals». commented Giovanni Ferrari.
The transaction was financed by a national banking syndicate led by MPS Capital Services and including BPER, Cariparma and GE Capital.